A 12-mer amino acid peptide SATTHYRLQAAN, denominated TK4, was isolated from a phage-display library with fibrosarcoma tumor-binding activity. In vivo biodistribution analysis of TK4-displaying phage showed a significant increased phage titer in implanted tumor up to 10-fold in comparison with normal tissues after systemic administration in mouse. Competition assay confirmed that the binding of TK4-phage to tumor cells depends on the TK4 peptide. Intravenous injection of 131I-labeled synthetic TK4 peptide in mice showed a tumor retention of 3.3% and 2.7%ID/g at 1- and 4-hour postinjection, respectively. Tumor-to-muscle ratio was 1.1, 5.7, and 3.2 at 1-, 4-, and 24-hour, respectively, and tumors were imaged on a digital -camera at 4-hour postinjection. The present data suggest that TK4 holds promise as a lead structure for tumor targeting, and it could be further applied in the development of diagnostic or therapeutic agent.

Original languageEnglish
Article number167045
JournalJournal of Biomedicine and Biotechnology
Publication statusPublished - 2010


ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Genetics
  • Molecular Biology
  • Health, Toxicology and Mutagenesis
  • Medicine(all)

Cite this

Wu, C. C., Lin, E. H., Lee, Y. C., Tai, C. J., Kuo, T. H., Wang, H. E., Luo, T. Y., Fu, Y. K., Chen, H. J., Sun, M. D., Wu, C. H., Wu, C. W., Leu, S. J., & Deng, W. P. (2010). Identification of a new peptide for fibrosarcoma tumor targeting and imaging in vivo. Journal of Biomedicine and Biotechnology, 2010, [167045]. https://doi.org/10.1155/2010/167045